Cargando…
Human Papillomavirus Vaccination After COVID-19
The current global novel coronavirus disease 2019 (COVID-19) pandemic threatens to derail the uptake of human papillomavirus (HPV) vaccination in low- and lower-middle income countries with major disruptions to routine immunization and the introduction of new vaccines delayed. This has a major impac...
Autores principales: | Toh, Zheng Quan, Russell, Fiona M, Garland, Suzanne M, Mulholland, Edward K, Patton, George, Licciardi, Paul V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962726/ https://www.ncbi.nlm.nih.gov/pubmed/33748668 http://dx.doi.org/10.1093/jncics/pkab011 |
Ejemplares similares
-
Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus
por: Toh, Zheng Quan, et al.
Publicado: (2019) -
Australia’s Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific
por: Toh, Zheng Quan, et al.
Publicado: (2021) -
Cervical Cancer Prevention Through HPV Vaccination in Low- and Middle-Income Countries in Asia
por: Toh, Zheng Quan, et al.
Publicado: (2017) -
A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination
por: Batmunkh, Tsetsegsaihan, et al.
Publicado: (2020) -
Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method
por: Toh, Zheng Quan, et al.
Publicado: (2020)